President Obama IS Women with Breast Cancer Being Cheated
Your Breast Cancer diagnosis is just average number. Yes a Gail number
92% Of Oncologist use something called a Gail Model for Breast Cancer Diagnosis & Treatment. Genomics is 72 % more effective than the Gail ModelWomen What Are We doing About a Cure for Breast Cancer Today. Genomic is The Next Generation to The Gail Model
Background:
The Breast Cancer Risk Assessment Tool (the Gail model) was designed by researchers at the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project as a tool for health care providers. The tool calculates a woman's risk of developing breast cancer within the next five years and within her lifetime (up to age 90). It takes into account seven key risk factors for breast cancer. • Age
• Age at first period
• Age at the time of the birth of her first child (or has not given birth)
• Family history of breast cancer (mother, sister or daughter)
• Number of past breast biopsies
• Number of breast biopsies showing atypical hyperplasia
• Race/ethnicity
Hybrid GenNxeix Researchers notice that the Breast Cancer Risk Assessment Tool does not calculate individual breast cancer risk, but rather the average risk for a group of women with similar risk factors. Thus, it is not clear what this risk means for any one woman. Say the model gives you a five-year risk of 1.7 percent. This means the tool estimates that 1.7 percent of women who have risk factors similar to your own will develop breast cancer over the next five years.
Women who have a five-year risk of 1.67 percent or higher (of the risk of an average 60-year-old woman) are classified as "high-risk". This score (a five-year risk of 1.67 percent or higher) is the cut-off for the FDA guidelines on tamoxifen and raloxifene use for breast cancer risk reduction.
Targeted therapies are transforming the way people treat cancer. These carefully designed drugs have already begun to make Genomic personalized medicine a reality and will continue to help doctors tailor cancer treatment based on the characteristics of each individual's cancer. It is important that health care professionals become familiar with the concept of targeted therapies so they can communicate with their patients about these new approaches and help patients make better-informed treatment decisions.
Treatment for breast cancer depends on the stage of the disease, but often includes surgery, radiation therapy, and chemotherapy. Some targeted therapies, including antihormone therapies and Herceptin® (trastuzumab), have also become part of standard treatment for breast cancer when a patient's tumor expresses the targets of these drugs. Preclinical experiments and clinical trials are currently underway to evaluate additional targeted therapies a
Hybrid GenNxeix Chief Science Officer says 75% of breast tumors rely on estrogen. These tumors are referred to as "estrogen dependent." Tumors that do not rely on estrogen for growth are called "estrogen independent."The epidermal growth factor receptor family consists of four cell surface receptors: EGF receptor, also called HER1; HER2/neu; HER3; and HER4. Binding of specific growth factors, or ligands, to three of these receptors causes them to interact, or dimerize, either with a receptor of the same type or with another family member. HER2 is called an "orphan receptor" because it does not interact directly with any ligand. Instead, it dimerizes with ligand-bound EGF receptor, HER3, or HER4.
Hybrid GenNxeix Chief Science Officer says 20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse when Using HybridNxeix Scr Kinase inhibitor with Treatment.
Results from an earlier analysis of the HERA trial, the 4-year follow-up results do not show a statistically significant difference in overall survival when not taking Using HybridNxeix Scr Kinase inhibitor with Treatment.
Again HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. Most Patients take Trastuzumab to extend survival of women with HER2-overexpressing metastatic breast .
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and, among other effects, causes breast cells to reproduce uncontrollably
HybridNxeix study 61 cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patients not treated with trastuzumab, of which 6 were later found to have recurrence. Differentially expressed genetic profiles were determined using human genome-wide Illumina Bead Microarrays. The differentially expressed genes for non-recurrence vs recurrence in the trastuzumab-
treated group were distinct from those in the same comparison group in the untreated group. Differential expression of key genes indentified in this study might offer an insight into a possible mechanism of trastuzumab resistance in breast carcinoma, and may emerge as potential predictive biomarkers indicative of trastuzumab resistance.science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
No comments:
Post a Comment